UroGen Pharma Ltd. — Director's Dealing 2024

Oct 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-10-08

Reporting Person: Degnan Chris (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-08	Restricted Stock Units	$	A	13450	Acquired		Ordinary Shares (13450)	Direct
2024-10-08	Employee Stock Option (right to buy)	$13.11	A	74142	Acquired	2034-10-08	Ordinary Shares (74142)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: 1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.

F3: 1/3 of the shares underlying the stock option will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.